CY1117004T1 - Παραγωγο τετραϋδροϊσοκινολιν-1-ονης ή αλας εξ' αυτου - Google Patents

Παραγωγο τετραϋδροϊσοκινολιν-1-ονης ή αλας εξ' αυτου

Info

Publication number
CY1117004T1
CY1117004T1 CY20151101112T CY151101112T CY1117004T1 CY 1117004 T1 CY1117004 T1 CY 1117004T1 CY 20151101112 T CY20151101112 T CY 20151101112T CY 151101112 T CY151101112 T CY 151101112T CY 1117004 T1 CY1117004 T1 CY 1117004T1
Authority
CY
Cyprus
Prior art keywords
tetrahydroisoquinolin
receptor
derivative
ibs
therapeutic agent
Prior art date
Application number
CY20151101112T
Other languages
English (en)
Inventor
Hiroyuki Hisamichi
Itsuro Shimada
Tsukasa Ishihara
Tomofumi Takuwa
Takafumi Shimizu
Noriko Ishikawa
Kyoichi Maeno
Norio Seki
Original Assignee
Seldar Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40075016&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117004(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seldar Pharma Inc. filed Critical Seldar Pharma Inc.
Publication of CY1117004T1 publication Critical patent/CY1117004T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

[ΠΡΟΒΛΗΜΑΤΑ] Να παρασχεθεί μια ένωση η οποία να μπορεί να χρησιμοποιηθεί ως ένας φαρμακευτικός παράγων, ειδικότερα δε ένας θεραπευτικός παράγων για σύνδρομο ευερέθιστων εντέρων (IBS). [ΜΕΣΑ ΓΙΑ ΤΗΝ ΕΠΙΛΥΣΗ ΤΩΝ ΠΡΟΒΛΗΜΑΤΩΝ] Ανευρίσκεται ότι ένα παράγωγο τετραϊδροϊσοκινολιν-1-όνης έχοντας μια ομάδα αμιδίου στην θέση-4 ή ένα φαρμακευτικώς αποδεκτό άλας εξ' αυτού έχει μια εξαιρετική ανταγωνιστική δραστηριότητα σε έναν υποδοχέα βομβεσίνης-2 (ΒΒ2). Ανευρίσκεται επίσης ότι και το παράγωγο τετραΐδροϊσοκινολιν-1-όνης είναι κατ' εξοχήν αποτελεσματικό και σε μη-φυσιολογικό εύρημα κοπράνων. Επομένως, το παράγωγο τετραϊδροϊσοκινολιν-1-όνης είναι χρήσιμο ως ένας θεραπευτικός παράγων για μια πάθηση που συσχετίζεται με έναν υποδοχέα της ΒΒ2, ειδικότερα δε του IBS.
CY20151101112T 2007-05-28 2015-12-08 Παραγωγο τετραϋδροϊσοκινολιν-1-ονης ή αλας εξ' αυτου CY1117004T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007140097 2007-05-28
EP08764654.3A EP2149561B1 (en) 2007-05-28 2008-05-26 Tetrahydroisoquinolin-1-one derivative or salt thereof

Publications (1)

Publication Number Publication Date
CY1117004T1 true CY1117004T1 (el) 2017-04-05

Family

ID=40075016

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151101112T CY1117004T1 (el) 2007-05-28 2015-12-08 Παραγωγο τετραϋδροϊσοκινολιν-1-ονης ή αλας εξ' αυτου

Country Status (23)

Country Link
US (5) US8486970B2 (el)
EP (1) EP2149561B1 (el)
JP (1) JP5336359B2 (el)
KR (3) KR101830566B1 (el)
CN (1) CN101668747B (el)
AU (1) AU2008255815B2 (el)
BR (1) BRPI0812359A2 (el)
CA (1) CA2688326C (el)
CY (1) CY1117004T1 (el)
DK (1) DK2149561T3 (el)
ES (1) ES2558677T3 (el)
HR (1) HRP20151336T1 (el)
HU (1) HUE026316T2 (el)
IL (1) IL202301A (el)
MX (1) MX2009012779A (el)
PL (1) PL2149561T3 (el)
PT (1) PT2149561E (el)
RS (1) RS54429B1 (el)
RU (1) RU2479578C2 (el)
SI (1) SI2149561T1 (el)
TW (1) TWI425945B (el)
WO (1) WO2008146774A1 (el)
ZA (1) ZA200908220B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029832A1 (de) 2009-09-09 2011-03-17 Vifor (International) Ag Neue thiazol- und oxazol-hepcidin-antagonisten
CN107109701B (zh) * 2014-09-16 2020-10-09 斯坦福国际研究院 通过光纤阵列扫描技术发现亲和试剂和催化剂
JP2019508496A (ja) * 2016-02-15 2019-03-28 チェム−フォルシュングスツェントルン フュル モレクラーレ メディツィン ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療法のためのtaf1阻害剤
EP3490980A4 (en) * 2016-07-22 2020-04-15 Virginia Commonwealth University PRODRUG AND PROTECTED FORMS OF 5-HYDROXYMETHYLFURFURANAL (5-HMF) AND ITS DERIVATIVES
EP3768266A4 (en) * 2018-03-20 2021-12-22 Merck Sharp & Dohme Corp. OXO-TETRAHYDRO-ISOQUINOLINE CARBOXYLIC ACIDS AS STING PROTEIN INHIBITORS
CN110563687B (zh) * 2019-07-23 2022-09-30 上海合全医药有限公司 一种4-(氨基甲基)色烷-3-醇的制备方法
EP4074314A1 (en) * 2021-04-15 2022-10-19 Valdospan GmbH Isoquinoline derivatives for use as antiviral and antitumour agents
CA3214899A1 (en) 2021-04-15 2022-10-20 Lutz Weber Isoquinoline derivatives for use as antiviral and antitumour agents
CN113603625B (zh) * 2021-08-12 2023-03-10 南京卓康医药科技有限公司 一种酮咯酸中间体的合成方法
WO2024083802A1 (en) 2022-10-17 2024-04-25 Valdospan Gmbh Isoquinoline derivatives as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
EP1155001A4 (en) 1999-02-22 2003-05-28 Lion Bioscience Ag ISOQUINOLEIN DERIVATIVES AND COMBINATORIAL ISOQUINOLEIN BANKS
WO2001047891A1 (fr) * 1999-12-28 2001-07-05 Eisai Co., Ltd. Composes heterocylciques contenant des groupes de sulfamide
ES2572332T3 (es) * 2000-10-31 2016-05-31 Rensselaer Polytech Inst 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides
AR035513A1 (es) * 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
DE10146867A1 (de) 2001-09-24 2003-04-24 Bayer Ag Tetrahydroisochinoline
AU2003249713A1 (en) * 2002-07-03 2004-01-23 Axys Pharmaceuticals, Inc. 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
ES2294475T3 (es) * 2003-03-07 2008-04-01 Eli Lilly And Company Derivados de nicotinamida g-sustituidos como antagonistas de receptores de opioides.
GB0305575D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
US7056930B2 (en) * 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
NZ546834A (en) * 2003-10-01 2010-03-26 Adolor Corp Spirocyclic heterocyclic derivatives and methods of their use
ES2257168B1 (es) * 2004-08-18 2007-06-01 Laboratorios Del Dr Esteve, S.A. Ligandos del receptor 5-ht7.
WO2006045096A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
US8163744B2 (en) 2005-03-18 2012-04-24 Nexuspharma, Inc. Tetrahydro-isoquinolin-1-ones for the treatment of cancer
US8101580B2 (en) * 2005-04-21 2012-01-24 Astellas Pharma Inc. Therapeutic agent for irritable bowel syndrome
RU2302417C1 (ru) 2006-03-14 2007-07-10 Иващенко Андрей Александрович 1-оксо-3-(1н-индол-3-ил)-1,2,3,4-тетрагидроизохинолины, способы их получения, комбинаторная библиотека и фокусированная библиотека
RU2303597C1 (ru) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
WO2008034039A2 (en) * 2006-09-15 2008-03-20 Nexuspharma Inc. Novel tetrahydro-isoquinolines
WO2008112715A2 (en) * 2007-03-12 2008-09-18 Vm Discovery Inc. Novel agents of calcium ion channel modulators
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
PT2149560E (pt) * 2007-05-22 2015-07-13 Astellas Pharma Inc Composto de tetra-hidroisoquinolina substituído na posição 1
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
US10532048B2 (en) 2020-01-14
PT2149561E (pt) 2016-01-07
US20170189390A1 (en) 2017-07-06
SI2149561T1 (sl) 2016-02-29
BRPI0812359A2 (pt) 2015-01-27
PL2149561T3 (pl) 2016-05-31
US20150359787A1 (en) 2015-12-17
RU2009148507A (ru) 2011-07-10
RU2479578C2 (ru) 2013-04-20
US9526719B2 (en) 2016-12-27
CN101668747A (zh) 2010-03-10
KR101830566B1 (ko) 2018-02-20
US20190000832A1 (en) 2019-01-03
KR20100020982A (ko) 2010-02-23
JP5336359B2 (ja) 2013-11-06
CA2688326A1 (en) 2008-12-04
TWI425945B (zh) 2014-02-11
US9150541B2 (en) 2015-10-06
TW200911251A (en) 2009-03-16
MX2009012779A (es) 2010-02-17
KR101580298B1 (ko) 2016-01-08
CN101668747B (zh) 2012-02-01
US20140058100A1 (en) 2014-02-27
AU2008255815A1 (en) 2008-12-04
AU2008255815B2 (en) 2012-02-02
KR20160139067A (ko) 2016-12-06
ES2558677T3 (es) 2016-02-08
WO2008146774A1 (ja) 2008-12-04
ZA200908220B (en) 2011-02-23
EP2149561B1 (en) 2015-09-09
DK2149561T3 (en) 2015-12-21
JPWO2008146774A1 (ja) 2010-08-19
IL202301A0 (en) 2010-06-30
US8486970B2 (en) 2013-07-16
RS54429B1 (en) 2016-04-28
HUE026316T2 (en) 2016-06-28
IL202301A (en) 2017-07-31
KR101682638B1 (ko) 2016-12-05
KR20150090262A (ko) 2015-08-05
CA2688326C (en) 2016-07-05
US20100227866A1 (en) 2010-09-09
EP2149561A1 (en) 2010-02-03
HRP20151336T1 (hr) 2016-01-15
US10016410B2 (en) 2018-07-10
EP2149561A4 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
CY1117004T1 (el) Παραγωγο τετραϋδροϊσοκινολιν-1-ονης ή αλας εξ' αυτου
CY1121043T1 (el) Θεραπευτικες ενωσεις
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CY1113352T1 (el) Ενωση σπειρο-δακτυλιου και χρηση αυτης για ιατρικους σκοπους
CY1119405T1 (el) Ενωση για την αναστολη ενζυμων
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
CY1119248T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
CY1116150T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
CY1111087T1 (el) Παραγωγα 5-(βενζ-(ζ)-υλιδενο)-θειαζολιδιν-4-ονης ως ανοσοκατασταλτικοι παραγοντες
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
AR077478A2 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
CY1114799T1 (el) Παραγωγα τετραϋδροκινολινης για τη θεραπεια διαταραχων μετατραυματικου στρες
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
CY1111789T1 (el) Ετεροκυκλικες ενωσεις
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
CY1113439T1 (el) Ενωση αζολιου
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
CY1115903T1 (el) Φλουρμπιπροφαινη και μυοχαλαρωτικοι συνδυασμοι
CY1113171T1 (el) Αντιφλεγμονωδεις παραγοντες